Story perspectives

Olema Pharmaceuticals Soars 100% on Roche's Breakthrough Results

11/18/2025

Summary

Story summary

Olema Pharmaceuticals surged over 100% to a four-year high after Roche (RHHBY) reported positive results for giredestrant.
Giredestrant is a selective estrogen receptor degrader (SERD) that outperformed aromatase inhibitors in early-stage breast cancer trials.
Oppenheimer analyst Matthew Biegler said the results were unexpected because investors focused on other Roche studies.
He raised Olema's palazestrant probability from 50% to 75% and its price target from $22 to $45.

History

Historical Context

In 2006, the FDA approved aromatase inhibitors for breast cancer treatment, enhancing patient outcomes. Recent trials by Roche revealed that giredestrant, a selective estrogen receptor degrader, surpassed these inhibitors, indicating a shift towards innovative therapies. This trend, exemplified by Olema Pharmaceuticals' stock rise, suggests a potential for improved survival rates and new standards in breast cancer management.

1 of 2

Story summary

Olema Pharmaceuticals surged over 100% to a four-year high after Roche (RHHBY) reported positive results for giredestrant.
Giredestrant is a selective estrogen receptor degrader (SERD) that outperformed aromatase inhibitors in early-stage breast cancer trials.
Oppenheimer analyst Matthew Biegler said the results were unexpected because investors focused on other Roche studies.
He raised Olema's palazestrant probability from 50% to 75% and its price target from $22 to $45.

1 / 2